NCT05142189 2025-11-12
LuCa-MERIT-1
BioNTech SE
Phase 1 Recruiting
Clinical Trials
10 trialsNCT06904131 2025-04-01
A Phase I Clinical Trial of CAR-T Cells for Advanced Gynecological Solid Tumors
Obstetrics & Gynecology Hospital of Fudan University
Phase NA Recruiting
NCT05293912 2025-03-18
SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.
Hangzhou Sumgen Biotech Co., Ltd.
Phase 1 Terminated
NCT05101109 2024-07-31
Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors
ABL Bio, Inc.
Phase 1 Completed
NCT03030287 2020-09-03
A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer
Mereo BioPharma
Phase 1 Completed
NCT03035253 2020-08-11
A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer
Mereo BioPharma
Phase 1 Terminated
NCT04076137 2019-09-03
Targeted T-cell Therapy in Solid Tumors
Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.
Phase EARLY_PHASE1 Unknown
NCT00014560 2018-05-03
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Dartmouth-Hitchcock Medical Center
Phase 1 Terminated
NCT00467506 2011-11-11
RIT in MTC
Nantes University Hospital
Phase 2 Completed
NCT00149019 2011-04-08
Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies.
Hadassah Medical Organization
Phase 2 Withdrawn